Drug Profile
Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics
Alternative Names: BMS-914143; Lambda - Eiger BioPharmaceuticals; PEG-IL-29 - ZymoGenetics; PEG-interferon lambda; PEG-interleukin-29 - ZymoGenetics; PEG-rIL-29 - ZymoGenetics; Peginterferon lambda-1a - Eiger BioPharmaceuticals/ZymoGenetics; Pegylated interferon lambda - Eiger BioPharmaceuticalsLatest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Bristol-Myers Squibb; Eiger BioPharmaceuticals, Inc.; University Health Network; ZymoGenetics
- Class Antivirals; Interferons; Interleukins
- Mechanism of Action Interleukin 29 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III COVID 2019 infections; Hepatitis D
- No development reported Multiple sclerosis
- Discontinued Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 31 Dec 2023 Eiger BioPharmaceuticals has patent protection for peginterferon lambda 1a in USA and Europe
- 31 Dec 2023 Eiger BioPharmaceuticals has patents pending for peginterferon lambda 1a in multiple countries worldwide
- 31 Dec 2023 Eiger Biopharmaceuticals plans to file BLA for Peginterferon lambda 1a for COVID-2019 infections and Hepatitis D